1
|
Schutte B and Ramaekers FC: Molecular
switches that govern the balance between proliferation and
apoptosis. Prog Cell Cycle Res. 4:207–217. 2000. View Article : Google Scholar
|
2
|
Jaleco S, Swainson L, Dardalhon V,
Burjanadze M, Kinet S and Taylor N: Homeostasis of naive and memory
CD4+ T cells: IL-2 and IL-7 differentially regulate the balance
between proliferation and Fas-mediated apoptosis. J Immunol.
171:61–68. 2003. View Article : Google Scholar
|
3
|
Mommers EC, van Diest PJ, Leonhart AM,
Meijer CJ and Baak JP: Balance of cell proliferation and apoptosis
in breast carcinogenesis. Breast Cancer Res Treat. 58:163–169.
1999. View Article : Google Scholar
|
4
|
Colitti M, Stefanon B and Wilde CJ:
Apoptotic cell death, bax and bcl-2 expression during sheep mammary
gland involution. Anat Histol Embryol. 28:257–264. 1999. View Article : Google Scholar
|
5
|
Heermeier K, Benedict M, Li M, Furth P,
Nuñez G and Hennighausen L: Bax and Bcl-xs are induced at the onset
of apoptosis in involuting mammary epithelial cells. Mech Dev.
56:197–207. 1996. View Article : Google Scholar
|
6
|
Kastan MB, Canman CE and Leonard CJ: P53,
cell cycle control and apoptosis: Implications for cancer. Cancer
Metastasis Rev. 14:3–15. 1995. View Article : Google Scholar
|
7
|
Leonard CJ, Canman CE and Kastan MB: The
role of p53 in cell-cycle control and apoptosis: Implications for
cancer. Important Adv Oncol. 33–42. 1995.
|
8
|
Van Parijs L, Ibraghimov A and Abbas AK:
The roles of costimulation and Fas in T cell apoptosis and
peripheral tolerance. Immunity. 4:321–328. 1996. View Article : Google Scholar
|
9
|
Akiyama K, Chen C, Wang D, Xu X, Qu C,
Yamaza T, Cai T, Chen W, Sun L and Shi S:
Mesenchymal-stem-cell-induced immunoregulation involves
FAS-ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell.
10:544–555. 2012. View Article : Google Scholar :
|
10
|
Schorr K, Li M, Krajewski S, Reed JC and
Furth PA: Bcl-2 gene family and related proteins in mammary gland
involution and breast cancer. J Mammary Gland Biol Neoplasia.
4:153–164. 1999. View Article : Google Scholar
|
11
|
Evan G, Harrington E, Fanidi A, Land H,
Amati B and Bennett M: Integrated control of cell proliferation and
cell death by the c-myc oncogene. Philos Trans R Soc Lond B Biol
Sci. 345:269–275. 1994. View Article : Google Scholar
|
12
|
Hoffman B and Liebermann DA: The
proto-oncogene c-myc and apoptosis. Oncogene. 17:3351–3357. 1998.
View Article : Google Scholar
|
13
|
Evan GI, Wyllie AH, Gilbert CS, Littlewood
TD, Land H, Brooks M, Waters CM, Penn LZ and Hancock DC: Induction
of apoptosis in fibroblasts by c-myc protein. Cell. 69:119–128.
1992. View Article : Google Scholar
|
14
|
Igney FH and Krammer PH: Immune escape of
tumors: Apoptosis resistance and tumor counterattack. J Leukoc
Biol. 71:907–920. 2002.
|
15
|
El Hage F, Abouzahr-Rifai S, Meslin F,
Mami-Chouaib F and Chouaib S: Immune response and cancer. Bull
Cancer. 95:57–67. 2008.(In French).
|
16
|
Zhao Y and Rangnekar VM: Apoptosis and
tumor resistance conferred by Par-4. Cancer Biol Ther. 7:1867–1874.
2008. View Article : Google Scholar :
|
17
|
Li J, Yu W, Tiwary R, Park SK, Xiong A,
Sanders BG and Kline K: α-TEA-induced death receptor dependent
apoptosis involves activation of acid sphingomyelinase and elevated
ceramide-enriched cell surface membranes. Cancer Cell Int.
10:402010. View Article : Google Scholar :
|
18
|
Olson M and Kornbluth S: Mitochondria in
apoptosis and human disease. Curr Mol Med. 1:91–122. 2001.
View Article : Google Scholar
|
19
|
Cappello F, Bellafiore M, Palma A and
Bucchieri F: Defective apoptosis and tumorigenesis: Role of p53
mutation and Fas/FasL system dysregulation. Eur J Histochem.
46:199–208. 2002. View
Article : Google Scholar
|
20
|
Ding HF and Fisher DE: Induction of
apoptosis in cancer: New therapeutic opportunities. Ann Med.
34:451–469. 2002. View Article : Google Scholar
|
21
|
Pan G, Vickers SM, Pickens A, Phillips JO,
Ying W, Thompson JA, Siegal GP and McDonald JM: Apoptosis and
tumorigenesis in human cholangiocarcinoma cells. Involvement of
Fas/APO-1 (CD95) and calmodulin. Am J Pathol. 155:193–203. 1999.
View Article : Google Scholar :
|
22
|
Fuxius S, Mross K, Mansouri K and Unger C:
Gemcitabine and interferon-alpha 2b in solid tumors: A phase I
study in patients with advanced or metastatic non-small cell lung,
ovarian, pancreatic or renal cancer. Anticancer Drugs. 13:899–905.
2002. View Article : Google Scholar
|
23
|
Morisaki T, Hirano T, Koya N, Kiyota A,
Tanaka H, Umebayashi M, Onishi H and Katano M: NKG2D-directed
cytokine-activated killer lymphocyte therapy combined with
gemcitabine for patients with chemoresistant metastatic solid
tumors. Anticancer Res. 34:4529–4538. 2014.
|
24
|
Li Q, Yuan Z, Yan H, Wen Z, Zhang R and
Cao B: Comparison of gemcitabine combined with targeted agent
therapy versus gemcitabine monotherapy in the management of
advanced pancreatic cancer. Clin Ther. 36:1054–1063. 2014.
View Article : Google Scholar
|
25
|
Sanna V, Pala N and Sechi M: Targeted
therapy using nanotechnology: Focus on cancer. Int J Nanomedicine.
9:467–483. 2014.
|
26
|
Xiao JY, Lee JY, Tokuhiro S, Nagataki M,
Jarilla BR, Nomura H, Kim TI, Hong SJ and Agatsuma T: Molecular
cloning and characterization of taurocyamine kinase from Clonorchis
sinensis: A candidate chemotherapeutic target. PLoS Negl Trop Dis.
7:e25482013. View Article : Google Scholar :
|
27
|
Toyota Y, Iwama H, Kato K, Tani J, Katsura
A, Miyata M, Fujiwara S, Fujita K, Sakamoto T, Fujimori T, et al:
Mechanism of gemcitabine-induced suppression of human
cholangiocellular carcinoma cell growth. Int J Oncol. 47:1293–1302.
2015.
|
28
|
Luo Y, Lin C, Zhang XY, Liang X, Fu M and
Feng FY: Relationship between the level of RRM1 expression and the
sensitivity to gemcitabine in the esophageal squamous cell
carcinoma cell lines. Zhonghua Zhong Liu Za Zhi. 31:660–663.
2009.(In Chinese).
|
29
|
Ohtsuka T, Ryu H, Minamishima YA, Macip S,
Sagara J, Nakayama KI, Aaronson SA and Lee SW: ASC is a Bax adaptor
and regulates the p53-Bax mitochondrial apoptosis pathway. Nat Cell
Biol. 6:121–128. 2004. View
Article : Google Scholar
|
30
|
Liu W, Luo Y, Dunn JH, Norris DA,
Dinarello CA and Fujita M: Dual role of apoptosis-associated
speck-like protein containing a CARD (ASC) in tumorigenesis of
human melanoma. J Invest Dermatol. 133:518–527. 2013. View Article : Google Scholar
|
31
|
Proell M, Gerlic M, Mace PD, Reed JC and
Riedl SJ: The CARD plays a critical role in ASC foci formation and
inflammasome signalling. Biochem J. 449:613–621. 2013. View Article : Google Scholar :
|